Drug intelligence / Profile preview

HuRicell-Hepa™

Development stage: Preclinical
Lead developer: Hurimbiocell
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HuRicell-Hepa™ is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy under development by Hurimbiocell for the treatment of various liver diseases, including hepatitis, liver cirrhosis, fatty liver, and liver cancer. The therapeutic approach utilizes the regenerative, anti-inflammatory, and immunomodulatory properties of mesenchymal stem cells to promote tissue repair and mitigate disease progression in the liver. As of the latest reports, the program has completed nonclinical Good Laboratory Practice (GLP) studies and is in the preclinical stage of development.

Brand names: HuRicell-Hepa™
Other names: HuRicell-Hepa

Beyond the preview

Go deeper on HuRicell-Hepa™.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuRicell-Hepa™.

Explore the full profile